Anti-Human CD257 (BAFF) (Tabalumab) – Dylight® 488

Anti-Human CD257 (BAFF) (Tabalumab) – Dylight® 488

Product No.: LT1411

- -
- -
Product No.LT1411
Clone
Tabalumab
Target
BAFF
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Tabalumab, CD257, BAFF, TNFSF13b, BLYS
Isotype
Human IgG1κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Cynomolgus Monkey/Rabbit
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Original antibody was raised against soluble human BAFF.
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Excitation Laser
Blue Laser (493 nm)
Additional Reported Applications For Relevant Conjugates ?
N
IP
WB
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tabalumab. Tabalumab neutralizes soluble human, cynomolgus monkey, and rabbit BAFF. Additionally, Tabalumab neutralizes membrane-bound BAFF. This product is for research use only.
Background
Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects.
Antigen Distribution
BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells.

Antigen Details

Ligand/Receptor
TACI, BCMA,APRIL ligand, BAFFR/BR3
PubMed
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer
.
Cell Biology
.
Costimulatory Molecules
.
Immuno-Oncology
.
Immunology
.
Signal Transduction
.
Stem Cell

References & Citations

1. Manetta, J. et al. (2014) J Inflamm Res. 7: 121–131
2. Clatworthy, MR. et al. (2013) Transplantation. 96(4): 413–420.
3. Lied, GA. and Berstad, A. (2011) Scand J Immunol. 73(1):1-7.
4. Büchler, JR. and Cano, MN. (1986) Jpn Heart J. 27(1):117-22.
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.